Newsroom - Tevogen
6 days ago · Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company’s Precision Cell Therapy Platform
Tevogen Bio to Become Publicly Listed on NYSE via Business …
Jun 29, 2023 · Tevogen Holdings common stock and warrants are expected to be listed on the NYSE under the new ticker symbol “TVGN”. Tevogen Bio is currently focused on developing its pipeline using its precision T cell platform, ExacTcell.
Home - Tevogen
Tevogen Bio is a late-stage biotech company harnessing the power of cytotoxic T lymphocytes (CTLs) with its ExacTcell platform. This pioneering technology produces scalable, rapidly available, unmodified allogeneic CTLs for the treatment of cancers, viral infections and the prevention of long-term complications of these conditions.
Tevogen Bio Inc. - Tevogen Bio Enters Into Agreement for Up to …
Jun 11, 2024 · Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts. WARREN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically ...
Technology - Tevogen
Tevogen’s commercial scale ready first generation manufacturing process already yields a highly efficient ratio of doses per cell donor. The second generation, Tevogen’s proprietary TCR-T process, is expected to dramatically increase the number of doses.
Press Releases Archive - Tevogen
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow Total eligible patients in the US exceed 2 million.
Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial …
Jan 23, 2023 · Tevogen is investigating its technology’s potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches.
Tevogen Bio Announces $8 Million Equity Investment
On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, entered into a securities purchase agreement with an investor pursuant to which the investor ...
Tevogen Bio Inc. - Tevogen Bio Announces Full Year 2023 Financial ...
May 1, 2024 · Tevogen Bio is in discussions to acquire cell therapy manufacturing facilities that are expected to provide Tevogen Bio with the capability for both clinical and commercial manufacturing of drug candidates from its ExacTcell technology platform.
News Details - Tevogen
Mar 20, 2024 · Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and Long COVID, retains activity against the currently dominant and highly mutated JN.1 strain based on a review of ...